Tweets
APP Pearls “Get to know your patients and any barriers they have that may impact their healthcare” - Natalie Lane, FNP-C
Dr. John Cush @RheumNow ( View Tweet )
1 week 5 days ago
Rapid rituximab infusions are safe & efficient. Metanalysis of 7 RCTs, 538 pts w/ autoimmune/rheumatic dz, showed infusions(RTX 1000 mg) of 90-120 min (w/ premedication) had low risk (3-15%) of mild (Grades 1, 2) infusion Rxns; only 6 Grade 3 Rxns https://t.co/uVKuhhc80F https://t.co/9EhyBpSaAE
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 week 5 days ago
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, https://t.co/Yg7DBOTW8o
Dr. John Cush @RheumNow ( View Tweet )
1 week 6 days ago
JAMA -- Full read review "Uveitis in Adults:"
- affects adults 20 to 50 years
- noninfectious anterior uveitis: corticosteroids 1st line Rx
- posterior noninfectious uveitis: DMARDs 1st line Rx; Biologics 2nd line
https://t.co/BJQkPtK2z2 https://t.co/0puqX5iieE
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 week 6 days ago
Best of 2025: Vitamin D for Prevention of Disease
JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults.
https://t.co/PFHO7x5nxH https://t.co/fvwzLgYGJe
Dr. John Cush @RheumNow ( View Tweet )
1 week 6 days ago
APP Pearls “When seeing a new patient, never assume that their preconceived or prior diagnosis is the only rheumatology condition that they have” - Lindsay Tom, PA-C
Dr. John Cush @RheumNow ( View Tweet )
1 week 6 days ago
Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology?
Recent large-scale clinical trials have broadened therapeutic options for SARD-ILD beyond immunosuppressants, offering new hope for patients with these serious conditions.
https://t.co/RLlOdEWTOa https://t.co/UI9cdJ5Ovd
Dr. John Cush @RheumNow ( View Tweet )
1 week 6 days ago
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest results from a Phase 3 trial presented at ACR 2025, sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/Tm8m43ZXBM https://t.co/GWLPR5y3d2
Dr. John Cush @RheumNow ( View Tweet )
1 week 6 days ago
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
https://t.co/2NFwTllLZa https://t.co/S7Cwzbgnde
Dr. John Cush @RheumNow ( View Tweet )
2 weeks ago
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025
https://t.co/yzQVt1fLKW https://t.co/hrbEeppZhW
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 weeks ago
APP Pearls “Point out to every patient with gout that poorly controlled gout will increase their risk of CV events and mortality” - Emma Bavage, NP
Dr. John Cush @RheumNow ( View Tweet )
2 weeks ago
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
Dr. John Cush @RheumNow ( View Tweet )
2 weeks ago
